Prescribing information


Prescribing information


Welcome to the RYDAPT® (midostaurin): On-demand webinars page. Here, you can access recordings from educational webinars hosted by experts in the field of acute myeloid leukaemia (AML) and organised by Novartis.


Preview of the video from the BSH 2020 Annual Scientific Meeting entitled The Current Treatment Paradigm for Acute Myeloid Leukaemia.

BSH 2020 Annual Scientific Meeting: The Current Treatment Paradigm for Acute Myeloid Leukaemia

Watch Dr Richard Dillon give an educational webinar at The British Society for Haematology Annual Scientific Meeting in November 2020, where he reviews the different approaches to diagnosis and management of patients with AML by stratifying risk and treatment allocation.

Video highlights and full webinar video from the Novartis-sponsored webinar event in November 2020 at The British Society for Haematology Annual Scientific Meeting.




Indication: RYDAPT is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by RYDAPT single agent maintenance therapy, in adult patients with newly diagnosed AML who are FLT3 mutation positive.1

AML, acute myeloid leukaemia; FLT3, fms-like tyrosine kinase 3.


  1. Rydapt Summary of Product Characteristics, 2021.
Rate this content: 
No votes yet
UK| March 2021 | 104382

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]